Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05414994 · ClinicalTrials.gov registry record
Assessment of the Ocular Microbiome in Health and Disease
A clinical trial of Eye Diseases and Microbial Colonization, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05414994: Recruiting study of Eye Diseases and Microbial Colonization, sponsored by Vanderbilt University Medical Center.
NCT05414994 is a study of Eye Diseases and Microbial Colonization that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 500 participants, below the 741,284-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05414994, a study of Eye Diseases and Microbial Colonization, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the health of the anterior segment. We will conduct a prospective, observational cohort study, including a longitudinal analysis of the ocular microbiome in adults.
Primary Outcome
Number of patients in middle Tennessee with a normal ocular microbiome by development of a normative database.
Conditions Studied
Interventions
- OTHER Eye swab
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2027-12-30 |
What NCT05414994 shows while recruiting
NCT05414994 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 741,284-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Eye Diseases appearing as the primary indexed condition, and to 1 intervention - of which Eye swab is the first listed.
NCT05414994 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05414994 about?
NCT05414994 is a clinical study titled "Assessment of the Ocular Microbiome in Health and Disease". The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the health of the anterior segment. We will conduct a prospective, observational cohort study, including a...
What is the current status of trial NCT05414994?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-09-07. Estimated completion is 2027-12-30.
What conditions does trial NCT05414994 study?
This clinical trial studies the following conditions: Eye Diseases, Microbial Colonization, Ophthalmopathy.
What interventions are being tested in trial NCT05414994?
The interventions under investigation include: Eye swab (OTHER).
Who is sponsoring clinical trial NCT05414994?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05414994 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05414994's enrollment target sits among peer trials
500 6th of 27 higher than 22 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
RECRUITING · NA
-
IRIS Registry: Intelligent Research in Sight Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI